In conclusion, we found a novel pharmacological role of galangin, that is galangin could effectively suppress the development and progress of osteoporosis through suppression of osteoclastogenesis via inhibition of p38, ERK and NF‐κB signalling pathways. This evidence concerns the gene NFKB1 and osteoporosis.